On January 22, the New York state legislature passed the New York Health Information Privacy Act (S929 / A2141) (“NYHIP”). If signed into law, NYHIP would join Washington and Nevada in a growing trend of states regulating consumer health information. Though NYHIP contains many similarities with laws in Washington and Nevada, there are a few unique provisions, as discussed below. Among them, NYHIP applies to “Regulated Health Information” or “RHI” that is defined as “any information that is reasonably linkable to an individual, or a device, and is collected or processed in connection with the physical or mental health of an individual.” Unlike the health privacy laws in Washington and Nevada, NYHIP does not provide an inclusive list of health data.

NYHIP would require regulated entities to obtain a “valid authorization” prior to processing RHI unless such processing is “strictly necessary” for certain enumerated purposes, including providing a product or service requested by the individual or certain limited internal business operations. NYHIP does not clarify what it means for a processing activity to be considered “strictly necessary.”

Where such an authorization is required, a valid authorization must, among other requirements: 

  • Be made at least twenty-four (24) hours after an individual creates an account or first uses the requested product or service; and
  • If multiple categories of processing are involved, provide an ability to “provide/withhold” authorization for each category separately.

The Governor is still awaiting the bill’s delivery to her desk. Once received by the Governor, she has 10 days to sign the bill, veto the bill, or sign the bill with “chapter amendments” (i.e., additional agreed-to changes that the bill sponsors commit to incorporating). The Governor’s failure to sign or veto the bill within the 10-day period means that it automatically becomes law.

Some other notable provisions of NYHIP include the following:

  • Scope & Exemptions:  NYHIP applies to “regulated entities” that (1) control the processing of RHI of state residents, (2) is located in New York and controls the processing of RHI, and (3) control the processing of RHI of an individual who is physically present in New York while that individual is in New York. This last clause is unique to NYHIP and could capture tourists visiting the state. NYHIP does not contain exemptions typically seen in other state privacy laws, such as exemptions for employee data, GLBA-regulated data, public data, or activities carried out for public health activities. NYHIP does, however, exempt HIPAA-covered data and information collected as part of a “clinical trial” conducted pursuant to human subject research frameworks.
  • Retention Schedule:  NYHIP requires regulated entities to maintain a publicly available retention schedule and dispose of an individual’s PHI pursuant to such schedule within a reasonable time once “it is no longer necessary to maintain” for the purposes for which it was collected.   
  • Service Provider Contract:  NYHIP provides a prescriptive list of what must be included within a contract between the service provider and the regulated entity. Specifically, NYHIP details that such agreement must, among other requirements, (1) impose a duty of confidentiality, (2) prohibit the service provider from combining RHI it receives with personal information it has from other individuals, and (3) require the service provider to cooperate with “reasonable assessments” by the regulated entity for purposes of evaluating compliance.
  • Enforcement:  NYHIP provides for enforcement by the state Attorney General, where they can seek civil penalties of up to $15,000 per violation or 20% of revenue obtained from NY consumers in the past year (whichever is greater). The AG also has authority to promulgate rules and regulations to effectuate the law. There is no express private right of action.
Photo of Libbie Canter Libbie Canter

Libbie Canter represents a wide variety of multinational companies on managing privacy, cyber security, and artificial intelligence risks, including helping clients with their most complex privacy challenges and the development of governance frameworks and processes to comply with U.S. and global privacy laws.

Libbie Canter represents a wide variety of multinational companies on managing privacy, cyber security, and artificial intelligence risks, including helping clients with their most complex privacy challenges and the development of governance frameworks and processes to comply with U.S. and global privacy laws. She routinely supports clients on their efforts to launch new products and services involving emerging technologies, and she has assisted dozens of clients with their efforts to prepare for and comply with federal and state laws, including the California Consumer Privacy Act, the Colorado AI Act, and other state laws. As part of her practice, she also regularly represents clients in strategic transactions involving personal data, cybersecurity, and artificial intelligence risk and represents clients in enforcement and litigation postures.

Libbie represents clients across industries, but she also has deep expertise in advising clients in highly-regulated sectors, including financial services and digital health companies. She counsels these companies — and their technology and advertising partners — on how to address legacy regulatory issues and the cutting edge issues that have emerged with industry innovations and data collaborations. 

Chambers USA 2024 ranks Libbie in Band 3 Nationwide for both Privacy & Data Security: Privacy and Privacy & Data Security: Healthcare. Chambers USA notes, Libbie is “incredibly sharp and really thorough. She can do the nitty-gritty, in-the-weeds legal work incredibly well but she also can think of a bigger-picture business context and help to think through practical solutions.”

Photo of Olivia Vega Olivia Vega

Olivia Vega provides strategic advice to global companies on a broad range of privacy, health care, and technology issues, including in technology transactions, mergers and acquisitions, and regulatory compliance. Within her practice, Olivia counsels clients on navigating the complex web of federal and…

Olivia Vega provides strategic advice to global companies on a broad range of privacy, health care, and technology issues, including in technology transactions, mergers and acquisitions, and regulatory compliance. Within her practice, Olivia counsels clients on navigating the complex web of federal and state privacy and data security laws and regulations, including on topics such as HIPAA, California’s Confidentiality of Medical Information Act, and the California Consumer Privacy Act. In addition, Olivia maintains an active pro bono practice.

Photo of Natalie Maas Natalie Maas

Natalie is an associate in the firm’s San Francisco office, where she is a member of the Food, Drug, and Device, and Data Privacy and Cybersecurity Practice Groups. She advises pharmaceutical, biotechnology, medical device, and food companies on a broad range of regulatory…

Natalie is an associate in the firm’s San Francisco office, where she is a member of the Food, Drug, and Device, and Data Privacy and Cybersecurity Practice Groups. She advises pharmaceutical, biotechnology, medical device, and food companies on a broad range of regulatory and compliance issues.

Natalie also maintains an active pro bono practice, with a particular focus on health care and reproductive rights.

Photo of Elizabeth Brim Elizabeth Brim

Elizabeth Brim is an associate in the firm’s Washington, DC office, where she is a member of the Data Privacy and Cybersecurity and Health Care Practice Groups and advises clients on a broad range of regulatory and compliance issues related to privacy and…

Elizabeth Brim is an associate in the firm’s Washington, DC office, where she is a member of the Data Privacy and Cybersecurity and Health Care Practice Groups and advises clients on a broad range of regulatory and compliance issues related to privacy and health care.

Elizabeth’s practice includes counseling clients on compliance with the complex web of health information privacy laws and regulations, such as HIPAA, the FTC’s Health Breach Notification Rule, and state medical and consumer health privacy laws as well as state consumer privacy and genetic privacy laws. She also advises clients on health care compliance issues, such as fraud and abuse, market access, and pricing and reimbursement activities.

Elizabeth routinely advises on regulatory compliance as part of transactions, clinical trial programs, collaborations and other activities that involve genetic data, and the development and operation of digital health products. As part of her practice, Elizabeth routinely counsels clients on drafting and negotiating privacy and health care terms with vendors and third parties and developing privacy notices and consent forms. In addition, Elizabeth maintains an active pro bono practice.

Elizabeth is an author of the American Health Law Association treatise, Pricing, Market Access, and Reimbursement Principles: Drugs, Biologicals and Medical Devices and the U.S. chapter of the Global Legal Insights treatise, Pricing & Reimbursement Laws and Regulations.

Photo of Ariel Dukes Ariel Dukes

Ariel Dukes is an associate in the firm’s Washington, DC office and a member of the Data Privacy and Cybersecurity Practice Group.

Ariel counsels clients on data privacy, cybersecurity, and artificial intelligence. Her practice includes partnering with clients on compliance with comprehensive privacy…

Ariel Dukes is an associate in the firm’s Washington, DC office and a member of the Data Privacy and Cybersecurity Practice Group.

Ariel counsels clients on data privacy, cybersecurity, and artificial intelligence. Her practice includes partnering with clients on compliance with comprehensive privacy laws, FTC and consumer protection laws and guidance, and laws governing the handling of health-related data. Additionally, Ariel routinely counsels clients on drafting and negotiating privacy terms with vendors and third parties, developing privacy notices and consent forms, and responding to regulatory inquiries regarding privacy and cybersecurity topics. Ariel also advises clients on trends in artificial intelligence regulations and helps design governance programs for the development and deployment of artificial intelligence technologies across a number of industries.